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Summary
Background Guidelines discourage the use of systemic corticosteroids for atopic
dermatitis (AD), but their use remains widespread.
Objectives To reach consensus among an international group of AD experts on the
use of systemic corticosteroids for AD.
Methods A survey consisting of statements accompanied by visual analogue scales rang-
ing from ‘strongly disagree’ to ‘neutral’ to ‘strongly agree’ was distributed to the Inter-
national Eczema Council (IEC). Consensus was reached in agreement on a statement if
< 30% of respondents marked to the left of ‘neutral’ towards ‘strongly disagree’.
Results Sixty of 77 (78%) IEC members participated. Consensus was reached on
12 statements, including that systemic corticosteroids should generally be
avoided but can be used rarely for severe AD under certain circumstances,
including a lack of other treatment options, as a bridge to other systemic thera-
pies or phototherapy, during acute flares in need of immediate relief, in anticipa-
tion of a major life event or in the most severe cases. If used, treatment should
be limited to the short term. Most respondents agreed that systemic cortico-
steroids should never be used in children, but consensus was not reached on that
statement. The conclusions of our expert group are limited by a dearth of high-
quality published evidence. If more stringent consensus criteria were applied
(e.g. requiring < 20% of respondents marking towards ‘strongly disagree’), con-
sensus would have been reached on fewer statements.
Conclusions Based on expert opinion from the IEC, routine use of systemic corticos-
teroids for AD is generally discouraged and should be reserved for special circum-
stances.
What’s already known about this topic?
• Despite recommendations against their use in practice guidelines, systemic corticos-
teroids are commonly used for atopic dermatitis (AD).
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What does this study add?
• The International Eczema Council reached consensus on circumstances in which
systemic corticosteroids can be used for AD, including a lack of other treatment
options, as a bridge to other systemic therapies or phototherapy, during acute
flares in need of immediate relief, in anticipation of a major life event, or in the
most severe cases.
• Clinicians should limit the use of systemic corticosteroids for severe AD to those
circumstances.
In clinical practice guidelines and position statements concern-
ing the management of atopic dermatitis (AD), the use of sys-
temic corticosteroids (CS), including prednisone,
hydrocortisone and celestone, is generally discouraged, with
use limited to special circumstances (Table 1).1–8 While sys-
temic CS can lead to rapid clearing of AD, their side-effect
profile and the risk of severe rebound flares after discontinua-
tion limit their use.9
Evidence of the benefits and risks of systemic CS in AD is
scarce.10 One randomized controlled trial (RCT) comparing
ciclosporin with prednisolone ended early owing to rebound
flares occurring in both groups, with 52% of subjects in the
prednisolone arm experiencing such a flare.11 Systemic CS use
in children with AD has been studied in two RCTs, but with
very small sample sizes.12,13 Based on their use in other con-
ditions, the long-term intermittent use of systemic CS is well
known to cause a multitude of side-effects,14–16 and even use
for 30 days or less has been associated with increased rates of
sepsis, venous thromboembolism and fracture.17 A recent sys-
tematic review of studies in children taking systemic CS for
> 2 weeks found significant increases in infections, growth
delay and obesity.18
Despite reasons for caution, systemic CS are still commonly
used for patients with moderate-to-severe AD. In a recent clin-
ical trial for adults with moderate-to-severe AD, which took
place in North America and Europe, 36% of participants
reported use of systemic CS in the year prior to the trial.19
Baseline data from a German registry of moderate-to-severe
AD revealed that 13% of participants had been on systemic CS
in the 3 months prior to enrollment,20 and in another German
study, 10% of patients with AD had used systemic CS over
2 years.21 In a survey of 61 U.K. consultant dermatologists,
42% listed systemic CS as their first-line systemic agent for
adult moderate-to-severe AD.22 In surveys of European and
North American paediatric dermatologists, oral CS were the
first-line systemic agents for severe paediatric AD for 31% and
5% of respondents, respectively.23,24
To address the concern of inappropriate use and overuse of
systemic CS for AD in clinical practice and to provide guidance
for clinicians as to what circumstances may constitute appropri-
ate use, a consensus process was initiated among the councillors
and associates of the International Eczema Council (IEC).
Materials and methods
The IEC (http://www.eczemacouncil.org/), founded in 2014,
is a global nonprofit organization whose membership consists
of 77 AD experts from 21 countries on five continents. All
Councilors and Associates are vetted for expertise in the field
of AD. In September 2016, an electronic questionnaire was
sent to the IEC membership regarding their use of systemic CS
for AD. On 29 September 2016, a panel discussion among IEC
members was held on the topic at the European Academy of
Dermatology and Venereology meeting in Vienna, Austria.
This informed the design of an electronic consensus survey,
developed by a group of IEC members (A.M.D., K.E.,
M.S.d.B.W., D.F.M., A.S.P., E.G.-Y.), which all IEC Councilors
and Associates were invited to take part in from 2 February to
14 March 2017. Study data were collected and managed using
REDCap electronic data capture tools hosted at Lifespan Health
System (Providence, RI, U.S.A.).25 The Brown University Insti-
tutional Review Board deemed that this project was exempt
from ethics review.
The survey consisted of 26 statements accompanied by
visual analogue scale (VAS) responses and six open-ended
questions (the entire questionnaire is available as
Appendix S1; see Supporting Information). The VAS repre-
sented a continuum from ‘strongly disagree’ to ‘neutral’ to
‘strongly agree’. Participants were asked to indicate with a sli-
der along the VAS whether they agreed or disagreed with a
statement.
Using rules similar to the Harmonizing Outcome Measures
for Eczema (HOME) initiative, consensus was reached when
< 30% of voters disagreed (i.e. if no more than 30% of par-
ticipants marked on the left side of the VAS towards ‘strongly
disagree’).26 These rules were developed and made known to
participants prior to survey completion. Participants’ responses
were anonymous.
As these consensus criteria are not universal, we conducted
post-hoc sensitivity analyses using more stringent consensus
criteria: (i) if no more than 20% of participants marked on
the left side of the VAS towards strongly disagree; and (ii) if
no more than 30% of voters marked within the left two-thirds
of the VAS (encompassing more of the ‘neutral’ range in addi-
tion to ‘strongly disagree’).
© 2017 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2018) 178, pp768–775
Systemic steroids for atopic dermatitis, A.M. Drucker et al. 769
Table 1 Approach to systemic corticosteroid (CS) use in atopic dermatitis (AD) in various clinical practice guidelines and position papers
Group publishing manuscript Selected statements on the use of CS for AD
ETFAD/EADV3 ‘[Systemic CS] should only be used for a few weeks for severe acute exacerbations due to the many
long-term side-effects. A typical regimen for severe acute exacerbations would be
methylprednisolone maximal 05 mg kg1 per day for 1–2 weeks and tapering over 1 month. . .In
severe chronic cases, starting of another oral immunosuppressive therapy while tapering the
[systemic CS] should be considered. [Systemic CS] must not be used for long periods of time due
to significant risk of severe side-effects’.
EDF, EADV, ETFAD, EFA, ESPD and
GA2LEN1
‘Systemic steroids have a largely unfavourable risk/benefit ratio for treatment of AE. Short-term (up
to 1 week) treatment may be an option to treat an acute flare in exceptional cases of atopic
eczema. Restrictive use, largely limited to adult patients with severe atopic eczema, is
recommended. The recommended daily dose should be adjusted to body weight. Long term use in
AE patients is not recommended. The indication for oral steroids in children should be handled
even more cautiously than in adults’.
AAD2 ‘Although systemic steroids are used by some providers to treat AD because they rapidly improve
clinical symptoms, caution is warranted to ensure their administration is time-limited and
judicious. . .Thus, although temporarily effective, systemic steroids (oral or parenteral) should
generally be avoided in adults and children with AD because the potential short- and long-term
adverse effects. . .largely outweigh the benefits. Systemic steroids may be considered for short-term
use in individual cases whereas other systemic or phototherapy regimens are being initiated and/
or optimized’.
Japanese Dermatological Association4 ‘Although they are known to be effective, long-term oral corticosteroid therapy induces various
serious systemic adverse reactions; therefore, long-term AD control with oral corticosteroids is not
recommended. If necessary, administration should be completed in a short period’.
KADA5 ‘Although systemic corticosteroids dramatically improve the clinical symptoms of AD, their
administration should generally be avoided because of adverse effects and the rebound
phenomenon. . .Once clinical improvement has been achieved, it is very important to taper the
dosage gradually over time to minimize the likelihood of a rebound effect. . .Continuous or
chronic intermittent use of systemic corticosteroids in AD is discouraged. However, acute usage
may be considered as a transitional therapy in severe, rapidly progressive, or debilitating cases
during the initiation of treatment with nonsteroidal systemic immunomodulatory agents that have
more favorable side-effect profiles, or phototherapy’.
Asia–Pacific Consensus Group for
Atopic Dermatitis6
‘There was a lack of consensus among the committee members regarding the use of oral
corticosteroid therapy. However, some clinicians find it useful to administrate short-term steroid
therapy, up to a maximum of 6 weeks, in combination with other standard modalities such as TCS
or TCI (e.g. for acute flare). Long-term systemic steroids have little to no value and should be
avoided in the management of AD due to adverse effects and rebound flare’.
Joint Task Force on Practice
Parameters: AAAAI, ACAAI, the
Joint Council of Allergy, Asthma
and Immunology7
‘The use of systemic corticosteroids, such as oral prednisone, might be required in the treatment of
severe chronic AD, although there is a paucity of controlled studies, despite widespread use of this
therapy. . .Nevertheless, the PRACTALL consensus report states that in cases of acute flare-up, while
patients might benefit from a short course of systemic therapy with corticosteroids, long-term use
and use in children should be avoided. . .If a short course of oral corticosteroid therapy is given
for a patient with severe AD, it is important to taper the dosage as it is discontinued. Intensified
skin care with topical anti-inflammatory therapy should also be instituted during the corticosteroid
taper to suppress rebound flaring of AD’.
ISPD AD treatment Guidelines
201630
‘Systemic corticosteroids are recommended only in adults and as short term bridging therapy while
buying time for other immunosuppressants to act. We do not recommend use of [systemic CS] in
children below 18 years for concern of high incidence of rebound flares on discontinuation,
immediate and long-term adverse effects’.
Dutch Society of Dermatology and
Venereology 20148
Oral corticosteroids are not recommended as prolonged monotherapy in the maintenance treatment
of serious atopic dermatitis. Oral corticosteroids can be given shortly as acute intervention therapy
for the treatment of exacerbations or as temporary co-medication to start up another
immunomodulatory agent, such as azathioprine, mycophenolate or methotrexate.a
EFTAD, European Task Force on Atopic Dermatitis; EADV, European Academy of Dermatology and Venereology; EDF, European Dermatology
Forum; EFA, European Federation of Allergy; EPSD, European Society of Pediatric Dermatology; GA2LEN, Global Allergy and Asthma Euro-
pean Network; AE, adverse event; AAD, American Academy of Dermatology; KADA, Korean Atopic Dermatitis Association; TCS, topical corti-
costeroid; TCI, topical calcineurin inhibitors; AAAAI, American Academy of Allergy, Asthma and Immunology; ACAAI, American College of
Allergy, Asthma and Immunology; ISPD, Indian Society for Pediatric Dermatology. aTranslated from Dutch by Dr Phyllis Spuls.
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Table 2 Results of the International Eczema Council consensus process
Statement
Proportion (%) of
respondents who marked
from neutral to strongly
agree
Statements reaching consensus
For CHILDREN under the age of 12, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids should generally be avoided in the treatment of severe
atopic dermatitis
51/59 (86)
For CHILDREN under the age of 12, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids may be used rarely for severe atopic dermatitis
41/58 (71)
For CHILDREN between 12 and 17 years of age, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids should generally be avoided in the treatment of severe
atopic dermatitis
47/56 (84)
For CHILDREN between 12 and 17 years of age, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids may be used rarely for severe atopic dermatitis
40/56 (71)
For ADULTS 18 and over, given concerns of side-effects and rebound flares on discontinuation,
systemic corticosteroids should generally be avoided in the treatment of severe atopic dermatitis
43/55 (78)
For ADULTS 18 and over, given concerns of side-effects and rebound flares on discontinuation,
systemic corticosteroids may be used rarely for severe atopic dermatitis
44/55 (80)
Specific circumstances
Systemic corticosteroids may be used for severe atopic dermatitis when there are no other viable
treatment options
44/54 (81)
Systemic corticosteroids may be used for severe atopic dermatitis as a bridge to other systemic agents
or phototherapy
39/54 (72)
Systemic corticosteroids may be used for severe atopic dermatitis in an acute flare in need of
immediate relief
42/54 (78)
Systemic corticosteroids may be used for severe atopic dermatitis in anticipation of an important life
event (e.g. wedding)
40/53 (75)
Systemic corticosteroids may be used for severe atopic dermatitis in cases that are the most severe
(e.g. erythrodermic)
38/53 (72)
Dose and timing considerations
If used, treatment with systemic corticosteroids for severe atopic dermatitis should be limited to
short-term use
50/53 (94)
Statements not reaching consensus
For CHILDREN under the age of 12, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids should never be used in the treatment of severe atopic
dermatitis
33/58 (57)
For CHILDREN under the age of 12, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids may be used regularly for severe atopic dermatitis
4/59 (7)
For CHILDREN between 12 and 17 years of age, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids should never be used in the treatment of severe atopic
dermatitis
30/56 (54)
For CHILDREN between 12 and 17 years of age, given concerns of side-effects and rebound flares on
discontinuation, systemic corticosteroids may be used regularly for severe atopic dermatitis
4/56 (7)
For ADULTS 18 and over, given concerns of side-effects and rebound flares on discontinuation,
systemic corticosteroids should never be used in the treatment of severe atopic dermatitis
21/55 (38)
For ADULTS 18 and over, given concerns of side-effects and rebound flares on discontinuation,
systemic corticosteroids may be used regularly for severe atopic dermatitis
2/55 (4)
Specific circumstances
Systemic corticosteroids may be used for severe atopic dermatitis not responding to topical therapy 19/54 (35)
Systemic corticosteroids may be used for severe atopic dermatitis not responding to other systemic
medications or phototherapy
35/54 (65)
Systemic corticosteroids may be used for severe atopic dermatitis in pregnancy 30/53 (57)
Dose and timing considerations
If used, treatment with systemic corticosteroids for severe atopic dermatitis should be limited to no
more than 2 weeks
36/52 (69)
If used, treatment with systemic corticosteroids for severe atopic dermatitis should be limited to no
more than 4 weeks
29/53 (55)
(continued)
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Results
Sixty of 77 (78%) IEC Councilors and Associates responded to
the survey, with 52 respondents completing the entire survey.
Respondents were from institutions in Australia (n = 2), Aus-
tria (n = 1), Brazil (n = 1), Canada (n = 2), China (n = 1),
Denmark (n = 3), France (n = 6), Germany (n = 7), India
(n = 1), Ireland (n = 1), Israel (n = 2), Italy (n = 2), Japan
(n = 5), Korea (n = 3), Netherlands (n = 4), Spain (n = 1),
Taiwan (n = 1), Tanzania (n = 1), U.K. (n = 3) and U.S.A.
(n = 13).
Consensus was reached on 12 statements related to use of
systemic CS in severe AD (Table 2). The percentage of respon-
dents who marked from ‘neutral’ to ‘strongly agree’ for each
statement is given in Table 2 and scatter plots of responses to
each statement can be found in Appendix S2 (see Supporting
Information).
For each age category (< 12 years, 12–17 years, adults),
consensus was reached that systemic CS should generally be
avoided but can be used rarely for severe AD. For each age
category, a substantial majority of respondents disagreed with
the statement that systemic CS should be used regularly for
severe AD. While consensus was not reached for any age
group on the statements that systemic CS should never be
used, > 50% of respondents agreed that systemic CS should
never be used in children (57%) and adolescents (54%).
The majority (65%) disagreed that nonresponse to topical
therapy was an indication for use of systemic CS. Consensus
was reached that among the appropriate circumstances for the
use of systemic CS in AD were a lack of other viable treatment
options, as a bridge to other systemic therapies or photother-
apy, acute flares in need of immediate relief, in anticipation
of a major life event or in cases that were the most severe.
Consensus was reached that, if used, systemic CS treatment of
severe AD should be limited to short-term use.
In their responses to the open-ended questions, individual
participants qualified their responses in several ways. Some
expressed strong support for the use of systemic CS, whereas
others expressed strong opposition.
In the sensitivity analysis using < 20% disagreement as a
more stringent cut-off, only five statements would have
reached consensus (Box S1; see Supporting Information). In
the sensitivity analysis in which no more than 30% of voters
marked within the left two-thirds of the VAS (counting more
of the ‘neutral’ range as disagreement), only three statements
would have reached consensus (Box S2; see Supporting Infor-
mation).
Discussion
Among a large international group of clinicians and research-
ers with expertise in AD, we reached consensus on 12 key
statements related to the use of systemic CS for severe AD.
The results provide a framework for clinicians caring for
patients with severe AD who are considering systemic CS as a
treatment option. Most notably, the group agreed on the state-
ments that, for patients of any age, systemic CS should gener-
ally be avoided but may be used rarely, and strongly opposed
the statements that systemic CS should be used regularly for
severe AD.
While our group agreed that systemic CS use should be
limited, consensus was reached on several clinical situations in
which systemic CS may be appropriate. These included dis-
ease-related factors, such as severe acute flares, as well as
patient-related factors, such as important life events. Addition-
ally, 72% of participants agreed that systemic CS could be
considered a bridging treatment to other systemic treatments.
While ciclosporin acts rapidly for acute AD flares, it may be
contraindicated in some patients. Methotrexate, azathioprine
and mycophenolate take several weeks to exert their clinical
effects and so, in some circumstances, taking advantage of the
rapid onset of action of systemic CS while waiting for a safer
long-term alternative to work may be appropriate. There are
also some circumstances in which other systemic treatment
options are not acceptable; for example, a recent diagnosis of
cancer along with a history of alcoholism would be a con-
traindication to the use of ciclosporin, azathioprine and
mycophenolate (owing to malignancy risk) and methotrexate
(owing to the risk of liver disease).
We were unable to reach consensus on many issues related
to dosing and duration of systemic CS use. However, the clear
majority of participants (94%) agreed that the use of systemic
CS should be limited to short periods of time. This is in keep-
ing with clinical practice guidelines.1–7 Our group did not
Table 2 (continued)
Statement
Proportion (%) of
respondents who marked
from neutral to strongly
agree
If used, treatment with systemic corticosteroids for severe atopic dermatitis should be limited to no
more than 6 weeks
25/53 (47)
If used, treatment with systemic corticosteroids for severe atopic dermatitis should be tapered slowly
over weeks
32/53 (60)
If used, treatment with systemic corticosteroids for severe atopic dermatitis should be low dose 22/52 (42)
If 70% of respondents marked from neutral to strongly agree, consensus was reached. The proportion of respondents who marked from neu-
tral to strongly agree on the visual analogue scale for each statement is given.
© 2017 The Authors. British Journal of Dermatology
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reach consensus on a definition of short-term use. The Euro-
pean Task Force on Atopic Dermatitis/European Academy of
Dermatology and Venereology task force position statement
on the treatment of AD suggests that a typical regimen of sys-
temic CS might be methylprednisolone 05 mg kg1 daily for
1–2 weeks tapered over 1 month,3 but there is no RCT evi-
dence for the safety or efficacy of this specific regimen.
Most respondents (but not enough for consensus) agreed
that systemic CS should never be used in children. Further,
while the circumstances agreed upon for the use of systemic
CS in AD can be applied to patients of all ages, they are less
likely to be applicable for young children. Most children will
have fewer comorbidities complicating the use of
immunomodulatory agents such as ciclosporin. As such, while
systemic CS should be used rarely for severe AD in general,
their use should be even more limited in children, particularly
given concerns regarding infection, growth delay and
increased rates of obesity.18
The divergence between guidelines discouraging systemic
CS use vs. their frequent use in routine clinical practice are a
concern. Ease of use, a rapid response in a distressed patient,
cost and familiarity of primary care physicians with systemic
CS for other conditions are all likely to contribute. The diver-
gence between treatments physicians suggest in guidelines in
a hypothetical clinical scenario and decisions they make when
dealing with an individual patient in one-to-one consultations
has been studied using a behavioural economics approach.27
Physicians often deviate from agreed best practice when con-
fronted with a distressed patient. Systematic approaches to bet-
ter understand the implementation gaps between guidelines
and practice have been advanced in a recent white paper by
the healthcare quality organization Joint Commission Interna-
tional, and may be applicable to systemic CS use for AD.28
The major strength of our study is the large, geographically
diverse group of IEC expert AD clinicians and researchers who
participated in the consensus process. During the panel discus-
sion preceding the formal consensus survey, it was clear that
clinical practice, even among experts, differed significantly
from country to country. Particularly given the sparsity of
RCT and high-quality nonrandomized study evidence to sup-
port any one viewpoint, keeping an open mind to different
practices is important. Despite the diversity of respondents,
there was over-representation from some countries, including
the U.S.A., which may have biased the results, and we would
have benefited from a higher response rate.
The major limitation of this project is the limited evidence to
support the consensus statements. While RCT evidence would
be ideal, many in the IEC would deem it unethical to subject
trial participants to systemic CS at this point. Additionally, RCT
follow-up is not likely to be long enough to detect many of the
long-term consequences of systemic CS use. The lack of data
likely also contributed to our inability to reach consensus on
specific dosing and duration recommendations for systemic CS.
Nonrandomized prospective registry studies being planned or
currently under way may help to answer some comparative effi-
cacy and safety questions in the AD population.20,29
As with any consensus project, our results are influenced by
the rules chosen to reach consensus. Using rules chosen a pri-
ori, we reached consensus on 12 statements. However, if we
had used stricter rules, as in our second sensitivity analysis,
we would have only reached consensus on three statements,
limiting the recommendations we could make. Another limita-
tion is the broad age range (0–12 years) used to define the
youngest group of children. More precise age categorization
may have yielded different results.
In conclusion, it is the consensus of the IEC that systemic
CS have a limited role in the treatment of severe AD in chil-
dren and adults. Clinicians should limit their use to special cir-
cumstances and always consider other treatment options. If
they are prescribed, they should be limited to short-term use
with a long-term treatment plan not involving systemic CS.
We hope that this serves to curb the overprescription of these
medications for patients with AD.
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